Sage Reports Q3 Growth with Zurzuvae, Ceases Major Depression Pursuit

Sage Therapeutics reported substantial growth in its third-quarter revenue, primarily driven by the success of its postpartum depression treatment, Zurzuvae. The drug achieved $11 million in revenue, marking a 49% increase from the previous quarter, indicating strong market reception and growing demand[1][2]. Despite this financial success, the company announced strategic shifts, including ceasing efforts to gain approval for major depressive disorder applications due to anticipated high costs and prolonged timelines[1][2]. As a part of these changes, Sage plans to discontinue its older drug, Zulresso, focusing resources on optimizing Zurzuvae's market potential[1].